Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.

ABSTRACT:

Aims

Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome. Our objective was to identify the possible molecular mechanisms of rivaroxaban that contribute to endothelial function.

Methods

Cell viability and growth of human umbilical vein endothelial cells (HUVEC) were registered. Gene expression studies comparing the effects of rivaroxaban and FXa were conducted by a selective RNA array and confirmed by protein quantification. Wound-healing experiments on HUVEC, platelet adhesion, enzymatic activity, and cell-based assays for fibrin formation were performed with rivaroxaban.

Results

Rivaroxaban (50 nM) only altered (>2 fold change) the expression of matrix metallo

SUBMITTER: Alvarez E 

PROVIDER: S-EPMC5777430 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature